ImpediMed Announces Appointment of Managing Director and CEO
Filed with ASX · · 5 pages · English
Earlier from ImpediMed
- ImpediMed Announces Management Reorganisation
- AstraZeneca Further Extends Clinical Trial Contract
- Appendix 4C & Quarterly Activities Report - Sep-22 Qtr
- New Corporate Oncology Account with GenesisCare
- 2022 Annual Report & Annual General Meeting Date
Later from ImpediMed
- New Version of NCCN Guidelines for Breast Cancer
- Appendix 4C & Quarterly Activities Report - Dec-22 Qtr
- S&P DJI Announces March 2023 Quarterly Rebalance
- NCCN Guidelines Now Recommend Bioimpedance Spectroscopy
- Appendix 4C & Quarterly Activities Report - Mar-23 Qtr
Follow ImpediMed into a list and get an email when it puts out news.
Follow ImpediMed